Trial Profile
A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TEMSO
- Sponsors Sanofi
- 27 Apr 2023 Results 3D conformational analysis of MP-RAGE images from the TEMSO trial , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 19 Sep 2022 Results of post-hoc analysis of two studies (TEMSO; NCT00134563 & long-term extension NCT00803049) assessing relationship between teriflunomide's effects on brain volume loss and cognition, published in the Multiple Sclerosis Journal.
- 28 Jun 2022 Results of post-hoc analysis of two studies (TEMSO (NCT00134563) and TOWER (NCT00751881)) assessing effect of teriflunomide on various dGM structures, presented at the 8th Congress of the European Academy of Neurology.